Form 4: Sionna Therapeutics Director Joshua Resnick Granted Non-Qualified Stock Options

Sionna Therapeutics, Inc. Director Joshua Resnick was granted 19,959 non-qualified stock options with an exercise price of $16.99, vesting by June 2026.

Summary

• Joshua Resnick, a Director of Sionna Therapeutics, Inc. (SION), was granted 19,959 non-qualified stock options on June 12, 2025.
• The options have an exercise price of $16.99 per share.
• The options are set to vest in full upon the earlier of June 12, 2026, or the date of the next annual meeting of Sionna Therapeutics, Inc., contingent on Mr. Resnick's continued service.
• The expiration date for these options is June 11, 2035.
• Mr. Resnick holds these options for the benefit of RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., and a separately managed account.
• He is obligated to turn over any net cash or stock received from exercising the options to RA Capital Management, L.P., which will offset advisory fees owed by the aforementioned funds and account.
• Mr. Resnick disclaims beneficial ownership of the stock option and the underlying common stock.

Sentiment

Score: 6

Explanation: The document reports a standard equity grant to a director, which is generally a neutral to slightly positive event as it aligns interests. However, the disclaimer of beneficial ownership by the director, due to the options being held for the benefit of investment funds, slightly dampens the direct positive impact for the individual.

Positives

• The grant of stock options aligns the director's interests with shareholder value, as the options become more valuable if the stock price increases above the exercise price.
• The options are granted at an exercise price of $16.99, indicating a valuation at the time of grant.

Negatives

• The reporting person, Joshua Resnick, disclaims beneficial ownership of the stock options and underlying common stock, as they are held for the benefit of RA Capital Management funds and will offset advisory fees, meaning the direct personal incentive for Mr. Resnick is limited.

Risks

• The value of the stock options is contingent on the future market price of Sionna Therapeutics, Inc. common stock exceeding the exercise price of $16.99.
• The vesting of the options is subject to Mr. Resnick's continued service on the vesting date.

Future Outlook

The options are set to vest in full upon the earlier of June 12, 2026, or the date of the next annual meeting of Sionna Therapeutics, Inc., provided the reporting person continues service.

Management Comments

• "Under the Reporting Person's arrangement with RA Capital Management, L.P. (the 'Adviser'), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the 'Fund'), the RA Capital Nexus Fund, L.P. (the 'Nexus Fund'), the RA Capital Nexus Fund III, L.P. (the 'Nexus Fund III'), and a separately managed account (the 'Account')."
• "The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund III and the Account to the Adviser."
• "The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock."

Industry Context

The grant of stock options is a common practice in the biotechnology and pharmaceutical industries to incentivize directors and align their interests with long-term company performance. The involvement of RA Capital Management, a prominent healthcare-focused investment firm, through its director on Sionna's board, highlights the strategic investment and governance influence of such institutional investors in emerging biotech companies.

Comparison to Industry Standards

• The grant of non-qualified stock options to a director is a standard form of equity compensation across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The exercise price of $16.99 reflects the market valuation at the time of the grant.
• The vesting schedule, tied to continued service, is typical for such grants, aiming to retain key personnel and align their long-term interests with the company's success.

Related Party Transactions

• Joshua Resnick, a director, holds the stock option for the benefit of RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., and a separately managed account, all managed by RA Capital Management, L.P.
• Mr. Resnick is obligated to turn over any net cash or stock received upon exercise of the option to RA Capital Management, L.P., which will offset advisory fees owed by the aforementioned funds and account.

Stakeholder Impact

• Shareholders: The grant of options is a form of non-cash compensation that aligns the director's interests with shareholder value creation, as the options gain value if the stock price increases. However, the director's disclaimer of beneficial ownership means the direct personal incentive is for the benefit of the RA Capital funds.
• Management/Employees: This represents a standard compensation practice for directors.

Next Steps

• The options are scheduled to vest in full upon the earlier of June 12, 2026, or the date of the next annual meeting of Sionna Therapeutics, Inc.
• Following vesting, the options may be exercised by the reporting person, with any net proceeds or stock turned over to RA Capital Management, L.P.

Key Dates

Keywords

Sionna Therapeutics, SION, stock option, director compensation, SEC filing, Form 4, RA Capital Management, equity grant, beneficial ownership